Perrigo Company plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Perrigo Company plc (PRGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2021-03-01
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2020 was 0.00 shares.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2019 was 0.00 shares, a 100.00% decline from fiscal 2018.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2018 was 521.00K shares, a 18.68% increase from fiscal 2017.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2017 was 439.00K shares, a 27.62% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|
| 2020-12-31 | 0.00 shares 10-K · filed 2021-03-01 | |
| 2019-12-31 | 0.00 shares 10-K · filed 2021-03-01 | |
| 2018-12-31 | 521.00K shares 10-K · filed 2020-02-27 | |
| 2017-12-31 | 439.00K shares 10-K · filed 2019-02-27 | |
| 2016-12-31 | 344.00K shares 10-K · filed 2018-03-01 | |
| 2015-12-31 | 0.00 shares 10-KT · filed 2016-02-25 | |
| 2015-06-27 | 181.00K shares 10-KT · filed 2016-02-25 | |
| 2014-06-28 | 165.00K shares 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |